Phospho-AURKB (T232) Antibody

What is the significance of T232 phosphorylation in Aurora Kinase B function?

T232 phosphorylation represents the active form of Aurora Kinase B (AURKB), which is essential for its kinase activity during mitosis. This specific phosphorylation occurs at threonine 232 within the activation loop of the kinase domain. When phosphorylated at T232, AURKB can effectively phosphorylate its downstream targets, particularly histone H3 at serine 10 (H3S10), which is crucial for proper chromosome condensation and segregation during cell division. Phosphorylation at T232 serves as a biomarker for active AURKB in experimental systems and can be used to assess the effects of various Aurora kinase inhibitors .

What is the intracellular localization pattern of active AURKB during different cell cycle phases?

Active Aurora Kinase B (phospho-T232) displays a dynamic localization pattern throughout the cell cycle. During mitosis, AURKB is localized to the midzone of the central spindle in late anaphase and becomes concentrated into the midbody during telophase and cytokinesis. It has been observed that AURKB co-localizes with gamma-tubulin in the midbody . This characteristic localization pattern is critical for AURKB's function in regulating the cleavage of polar spindle microtubules and orchestrating cytokinesis. AURKB is primarily expressed during S and G2/M phases of the cell cycle, with expression being notably up-regulated in cancer cells during M phase .

What are the optimal sample preparation methods for detecting phospho-AURKB (T232) by Western blot?

For optimal detection of phospho-AURKB (T232) by Western blot, follow these methodological guidelines:

• Sample preparation: Harvest cells during mitosis (when AURKB is most active) using appropriate synchronization methods or mitotic shake-off.

• Lysis conditions: Use a phosphatase inhibitor-containing lysis buffer to preserve phosphorylation state.

• Loading control: Include HeLa cell lysate as a positive control, as recommended in the antibody specifications .

• Expected molecular weight: Look for a band approximately 39 kDa in size corresponding to Aurora Kinase B .

• Antibody dilution: Use a dilution range of 1:500-1:2000 for Western blotting applications .

• Secondary antibody: Use HRP-linked rabbit IgG for detection .

For validation, verification of specificity can be performed using AURKB knockdown by siRNA, which would result in decreased phospho-AURKB T232 signal .

How can I optimize immunofluorescence protocols for phospho-AURKB (T232) detection?

To optimize immunofluorescence detection of phospho-AURKB (T232), consider these methodological approaches:

• Fixation method: Use 4% paraformaldehyde for 15-20 minutes at room temperature to preserve phospho-epitopes.

• Permeabilization: A gentle permeabilization with 0.2% Triton X-100 for 10 minutes is recommended.

• Blocking: Block with 5% BSA in PBS to reduce non-specific binding.

• Antibody dilution: Use a dilution range of 1:200-1:1000 for immunofluorescence applications .

• Counter-staining: Consider co-staining with markers for specific cell cycle phases or structures (e.g., α-tubulin for microtubules).

• Controls: Include cells treated with phosphatase to serve as negative controls.

To validate results, look for the characteristic localization pattern: AURKB (phospho T232) should be primarily detected in the nuclei of dividing cells, with specific enrichment at the midzone during anaphase and midbody during telophase/cytokinesis .

What controls should be included when evaluating AURKB inhibitors using phospho-AURKB (T232) antibodies?

When evaluating AURKB inhibitors using phospho-AURKB (T232) antibodies, include these essential controls:

• Positive control: Untreated cells during M-phase when AURKB is naturally active.

• Vehicle control: Cells treated with the solvent used to dissolve the inhibitor.

• Dose response: Multiple concentrations of the inhibitor to establish dose-dependent effects.

• Time course: Different treatment durations to determine optimal inhibition timeline.

• Specificity controls:

  • Treatment with Aurora A-specific inhibitors (e.g., Aurora A inhibitor I) should not affect phospho-AURKB T232 levels .

  • AURKB-specific inhibitors (e.g., hesperadin, TAK-901, danusertib) should decrease phospho-AURKB T232 levels .

• Genetic validation: AURKB knockdown using siRNA as a positive control for specificity .

• Downstream target assessment: Monitor phosphorylation of AURKB substrates like histone H3 at serine 10 (H3S10ph) to confirm functional inhibition .

Researchers should also consider monitoring cell proliferation using assays such as CCK8 to correlate decreased phospho-AURKB levels with functional outcomes like inhibited cell proliferation .

How does phospho-AURKB (T232) expression correlate with cancer progression?

Phospho-AURKB (T232), representing the active form of Aurora Kinase B, has been implicated in cancer progression through multiple mechanisms. Integrated analysis of The Cancer Genome Atlas (TCGA) data suggests AURKB plays a role in accelerating oncogenesis and metastasis . Research indicates that AURKB expression is up-regulated in cancer cells specifically during M phase, suggesting its potential involvement in the dysregulated cell division characteristic of cancer cells .

In studies using uveal melanoma (UM) cell lines, inhibition of AURKB activity through hesperadin, TAK-901, and danusertib treatment decreased phospho-AURKB T232 levels, which correlated with reduced cell proliferation. Further validation through siRNA-mediated AURKB knockdown also severely inhibited UM cell proliferation, confirming AURKB's oncogenic role . This evidence collectively supports that active phosphorylated AURKB contributes to cancer cell proliferation and survival, making it both a biomarker for aggressive disease and a potential therapeutic target.

What methodological approaches can detect changes in AURKB activity in response to experimental cancer therapies?

To detect changes in AURKB activity in response to experimental cancer therapies, researchers can employ several complementary methodological approaches:

• Western blot analysis:

  • Quantify phospho-AURKB T232 levels normalized to total AURKB

  • Monitor downstream targets like H3S10ph (phospho-histone H3 at serine 10)

  • Expected band size for AURKB is approximately 39 kDa

• Immunofluorescence microscopy:

  • Assess changes in subcellular localization of phospho-AURKB

  • Quantify signal intensity at mitotic structures

  • Combine with cell cycle markers to determine phase-specific effects

• Functional assays:

  • Cell proliferation assays (e.g., CCK8) to correlate molecular changes with phenotypic outcomes

  • Analysis of mitotic abnormalities and cytokinesis defects

  • Cell cycle distribution analysis by flow cytometry

• Genetic approaches:

  • siRNA knockdown of AURKB as a positive control for antibody specificity and phenotype validation

  • Rescue experiments with phospho-mimetic or phospho-dead AURKB mutants

When testing Aurora kinase inhibitors, researchers should include multiple inhibitors with different specificities to distinguish between effects on AURKB versus other Aurora kinase family members .

How can phospho-AURKB (T232) antibodies be used to study chromosomal remodeling in cancer cells?

Phospho-AURKB (T232) antibodies provide valuable tools for studying chromosomal remodeling in cancer cells through several research approaches:

• Chromatin immunoprecipitation (ChIP) assays:

  • Using phospho-AURKB (T232) antibodies for ChIP can help identify genomic regions where active AURKB is associated with chromatin

  • This approach can reveal AURKB's involvement in regulating specific gene expressions, particularly telomeric genes as suggested by research

• Co-immunoprecipitation studies:

  • Identify interaction partners of active AURKB in chromatin remodeling complexes

  • Map protein-protein interaction networks involved in chromosomal structure regulation

• Immunofluorescence co-localization analysis:

  • Examine spatial relationships between phospho-AURKB and chromatin markers

  • Analyze co-localization with histone modifications, particularly H3S10ph, H3K9me2/3, which are known substrates or associated markers

• Live cell imaging with labeled antibodies:

  • Track dynamic changes in AURKB activity during chromosomal remodeling events

  • Correlate with structural changes in chromatin organization

• Effects on telomeric regions:

  • Research indicates AURKB enhances chromosomal remodeling of telomeric genes

  • Researchers can examine AURKB's relationship with telomere-associated proteins like TERT

These methodological approaches can reveal how active AURKB contributes to chromosomal instability in cancer and identify potential therapeutic vulnerabilities.

What is the role of phospho-AURKB (T232) in embryonic development?

Phospho-AURKB (T232), the active form of Aurora Kinase B, plays significant roles in embryonic development as evidenced by its consistent expression pattern in developing tissues. Research has specifically examined its function in embryonic submandibular gland (E-SMG) morphogenesis. Immunolabelling studies of mouse embryos with anti-AURKB (phospho T232) antibodies have revealed consistent expression of the active kinase throughout different stages of embryonic SMG development .

The active form of AURKB was found to be mainly expressed in the nuclei of bud epithelial cells, with additional sporadic staining observed in stromal cells during embryonic development. This expression pattern was consistent across various developmental stages, suggesting that phospho-AURKB has essential functions in tissue morphogenesis and organization during embryogenesis .

Functionally, inhibition of Aurora Kinase B activity has been shown to disrupt normal development, indicating that the active phosphorylated form of the enzyme is not merely present but is functionally required for proper embryonic development .

How can researchers optimize immunohistochemical detection of phospho-AURKB in embryonic tissues?

Optimizing immunohistochemical detection of phospho-AURKB in embryonic tissues requires special considerations due to the delicate nature of embryonic samples:

• Sample preparation:

  • Fix embryonic tissues promptly with 4% paraformaldehyde

  • Consider shorter fixation times (4-8 hours) for smaller embryonic samples

  • Use serial sectioning techniques to identify specific developmental structures (as demonstrated in E-SMG studies)

• Antigen retrieval:

  • Use gentle antigen retrieval methods to preserve tissue morphology

  • Citrate buffer (pH 6.0) heat-induced epitope retrieval is often effective

  • Optimize retrieval time carefully for embryonic tissues (typically shorter than adult tissues)

• Antibody conditions:

  • Dilution range: 1:100-1:300 for IHC applications

  • Extended incubation times at 4°C may improve signal with reduced background

  • Consider using signal amplification systems for detecting low abundance signals

• Controls and validation:

  • Include age-matched control tissues

  • Use adult murine tissues with known AURKB expression (e.g., adult SMG) as reference points

  • Include negative controls by omitting primary antibody

• Counterstaining:

  • Use H&E staining on serial sections to identify specific developmental structures

  • Consider nuclear counterstains (e.g., DAPI, hematoxylin) to highlight nuclear localization of phospho-AURKB

Following these methodological approaches will help researchers achieve optimal detection of phospho-AURKB in embryonic tissues while preserving morphological context.

What experimental approaches can determine if phospho-AURKB (T232) activity is necessary rather than merely coincidental in developmental processes?

To determine whether phospho-AURKB (T232) activity is causally necessary rather than merely coincidental in developmental processes, researchers can employ these experimental approaches:

• Pharmacological inhibition studies:

  • Treat developing embryos or organ cultures with specific AURKB inhibitors (hesperadin, TAK-901, danusertib)

  • Use dose-response experiments to identify the minimal effective concentration

  • Include Aurora A-specific inhibitors as controls to confirm specificity

  • Assess developmental outcomes using morphological and functional parameters

• Genetic manipulation approaches:

  • Conditional knockout models with tissue-specific or temporally controlled AURKB deletion

  • siRNA-mediated knockdown in ex vivo organ culture systems

  • CRISPR/Cas9-mediated genome editing to create phospho-dead (T232A) or phospho-mimetic (T232D/E) AURKB mutants

• Rescue experiments:

  • After inhibition or knockdown, attempt rescue with wild-type AURKB

  • Compare rescue efficacy between wild-type and phospho-dead (T232A) AURKB variants

  • This approach can definitively link the phosphorylation state to functional outcomes

• Temporal analysis:

  • Map the precise timing of AURKB phosphorylation relative to key developmental milestones

  • Use timed inhibition studies to identify critical windows when phospho-AURKB activity is essential

• Downstream pathway analysis:

  • Monitor known AURKB targets like H3S10ph during development

  • Identify developmental phenotypes that correlate specifically with loss of AURKB-dependent phosphorylation events

Evidence from submandibular gland development studies already suggests that inhibition of Aurora Kinase B activity disrupts normal development, supporting a necessary rather than coincidental role .

How can phospho-specific antibodies like phospho-AURKB (T232) be validated to ensure they're detecting the correct phosphorylated residue?

Validating phospho-specific antibodies such as phospho-AURKB (T232) requires a multi-faceted approach to ensure specific detection of the correct phosphorylated residue:

• Phosphatase treatment controls:

  • Treat one sample with lambda phosphatase before immunoblotting

  • The phospho-specific signal should disappear while total AURKB remains detectable

• Competing peptide validation:

  • Pre-incubate antibody with phosphorylated and non-phosphorylated peptides

  • The phosphorylated peptide should block signal while non-phosphorylated peptide should not

  • This approach follows the manufacturing process where antibodies are first purified against phosphorylated immunizing peptides and then cross-adsorbed against non-phosphorylated forms

• Mutagenesis studies:

  • Express wild-type AURKB alongside T232A (phospho-dead) mutant

  • The antibody should detect wild-type but not the T232A mutant

• Kinase inhibitor specificity:

  • Treat samples with AURKB inhibitors (hesperadin, TAK-901, danusertib)

  • Monitor decrease in phospho-AURKB signal

  • Include Aurora A inhibitors as negative controls, which should not affect T232 phosphorylation

• Genetic knockdown:

  • Reduce AURKB expression using siRNA or CRISPR

  • Confirm corresponding reduction in phospho-AURKB signal

• Mass spectrometry validation:

  • Perform immunoprecipitation using the phospho-specific antibody

  • Confirm the presence of phosphorylated T232 by mass spectrometry

These rigorous validation approaches ensure the antibody's specificity for the phosphorylated T232 residue of AURKB.

What are the challenges in quantifying phospho-AURKB (T232) levels across different experimental conditions?

Quantifying phospho-AURKB (T232) levels across different experimental conditions presents several technical challenges that researchers should address methodologically:

Addressing these methodological challenges systematically will improve the accuracy and reproducibility of phospho-AURKB (T232) quantification across experimental conditions.

How can researchers troubleshoot contradictory results when phospho-AURKB (T232) activity doesn't correlate with expected phenotypes?

When researchers encounter contradictory results where phospho-AURKB (T232) activity doesn't correlate with expected phenotypes, the following troubleshooting approaches can help resolve discrepancies:

• Timing considerations:

  • AURKB phosphorylation is transient and cell cycle-dependent

  • Solution: Perform detailed time-course experiments to capture dynamic changes

  • Examine multiple time points after treatment or stimulation

• Antibody specificity verification:

  • Confirm antibody is detecting specifically phospho-T232 AURKB

  • Solution: Perform validation experiments described in FAQ 5.1

  • Consider using multiple antibodies from different vendors as cross-validation

• Functional redundancy analysis:

  • Other kinases may compensate for AURKB inhibition

  • Solution: Examine activity of related kinases (Aurora A, C) and potential compensatory pathways

  • Consider combination approaches targeting multiple redundant pathways

• Context-dependent effects:

  • Cell type or tissue-specific factors may influence AURKB function

  • Solution: Test hypotheses across multiple cell lines or model systems

  • Examine microenvironmental factors that might influence outcomes

• Threshold effects:

  • Partial inhibition may be insufficient to produce phenotypic changes

  • Solution: Create quantitative dose-response curves relating phospho-AURKB levels to phenotypic outcomes

  • Determine minimum threshold of inhibition required for phenotypic effects

• Post-translational modification interplay:

  • Other modifications may override or synergize with T232 phosphorylation

  • Solution: Examine other known AURKB modifications simultaneously

  • Consider mass spectrometry analysis to identify additional modifications

• Experimental approach diversification:

  • Different methods have distinct limitations

  • Solution: Combine genetic (siRNA knockdown) , pharmacological (specific inhibitors) , and mutation-based approaches

  • Triangulate findings using complementary methodologies

By systematically addressing these potential sources of discrepancy, researchers can resolve contradictory results and develop a more nuanced understanding of phospho-AURKB (T232) function in their specific experimental context.